Japanese Transgenic Obtains Patent For Pancreatic Cancer Antibody Diagnostic Technology
This article was originally published in PharmAsia News
Executive Summary
Japanese biotech venture company Transgenic obtained a patent for pancreatic cancer antibody diagnostic technology. The technology uses antibodies to detect a protein unique to pancreatic cancer patients. Transgenic developed the technology through a joint research project with Japan's National Cancer Center in 2007. Using genetically engineered mice, Transgenic developed the antibody that can be easily combined with the protein. Currently there are few cancer makers for pancreatic cancer diagnose. (Click here for more - Japanese language